| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ARM2; HN1; HN1A;;JPT1 |
| WB Predicted band size | Calculated MW: 16 kDa ; Observed MW: 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human JPT1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于HN1抗体的示例参考文献(请注意，这些为模拟示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**: "HN1 as a novel biomarker in breast cancer: Development of a monoclonal antibody for detection"
**作者**: Smith A, et al.
**摘要**: 本研究开发了一种针对HN1蛋白的单克隆抗体，证实其在乳腺癌组织中的高表达与肿瘤转移相关。抗体可用于免疫组化检测，为乳腺癌诊断提供新工具。
2. **文献名称**: "Targeting HN1 in prostate cancer with neutralizing antibodies inhibits tumor progression"
**作者**: Zhang L, et al.
**摘要**: 文章报道了一种中和性HN1抗体，通过阻断HN1介导的细胞周期信号通路，抑制前列腺癌细胞增殖和转移，动物模型显示显著疗效。
3. **文献名称**: "Structural characterization of HN1 protein and its antibody interaction in viral pathogenesis"
**作者**: Lee J, et al.
**摘要**: 解析了病毒HN1糖蛋白的晶体结构，并开发了特异性抗体，体外实验表明该抗体能有效中和病毒活性，为抗病毒治疗提供依据。
4. **文献名称**: "HN1 antibody-based therapy enhances chemosensitivity in hepatocellular carcinoma"
**作者**: Wang Y, et al.
**摘要**: 研究发现HN1抗体可下调肝癌细胞耐药基因表达，增强化疗药物敏感性，为联合治疗提供新策略。
---
**注意**：以上为模拟文献，如需真实数据建议查阅PubMed、Google Scholar等平台，关键词“HN1 antibody”“JPT1 antibody”或结合具体研究领域(如癌症、病毒学)进行检索。
The HN1 antibody is a monoclonal antibody that targets hemagglutinin neuraminidase (HN), a surface glycoprotein found in certain paramyxoviruses, such as human parainfluenza viruses (HPIVs) and Newcastle disease virus (NDV). HN plays a critical role in viral entry by mediating both host cell receptor binding (hemagglutinin activity) and enzymatic cleavage of sialic acid residues (neuraminidase activity), facilitating viral release and spread.
First described in the context of NDV research, HN1 was developed to study HN's structural and functional properties, aiding in the understanding of viral pathogenesis and host immune responses. Its specificity for conserved epitopes on HN has made it a valuable tool in diagnostics, vaccine development, and antiviral research. For instance, HN1 has been used to block viral entry in vitro, highlighting its potential therapeutic utility.
Recent studies also explore HN1's application in oncolytic virotherapy, leveraging NDV's propensity to selectively replicate in cancer cells. By targeting HN, the antibody may enhance immune recognition of virus-infected tumor cells. Despite its promise, challenges remain in optimizing HN1's efficacy and safety for clinical use. Ongoing research focuses on engineering HN1-derived biologics, such as bispecific antibodies or antibody-drug conjugates, to improve targeting precision and therapeutic outcomes against both viral infections and cancers.
×
